BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A
Young Kul Jung
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
The first two authors contributed equally to this work.Search for more papers by this authorChang Ho Jung
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
The first two authors contributed equally to this work.Search for more papers by this authorCorresponding Author
Yeon Seok Seo
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Correspondence
Dr Yeon Seok Seo, Department of Internal Medicine, Korea University College of Medicine, 126-1, 5-Ga, Anam-Dong, Seongbuk-Gu, Seoul, 136-705, Korea. Email: [email protected]
Dr Ji Hoon Kim, Department of Internal Medicine, Korea University College of Medicine, 97, Guro-Dong Gil, Guro-Dong, Guro-Ku, Seoul, 152-703, Korea. Email: [email protected]
Search for more papers by this authorCorresponding Author
Ji Hoon Kim
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Correspondence
Dr Yeon Seok Seo, Department of Internal Medicine, Korea University College of Medicine, 126-1, 5-Ga, Anam-Dong, Seongbuk-Gu, Seoul, 136-705, Korea. Email: [email protected]
Dr Ji Hoon Kim, Department of Internal Medicine, Korea University College of Medicine, 97, Guro-Dong Gil, Guro-Dong, Guro-Ku, Seoul, 152-703, Korea. Email: [email protected]
Search for more papers by this authorTae Hyung Kim
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorYang Jae Yoo
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorSeong Hee Kang
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorSun Young Yim
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorSang Jun Suh
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorHyunggin An
Biostatistics, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorHyung Joon Yim
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorJong Eun Yeon
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorKwan Soo Byun
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorSoon Ho Um
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorYoung Kul Jung
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
The first two authors contributed equally to this work.Search for more papers by this authorChang Ho Jung
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
The first two authors contributed equally to this work.Search for more papers by this authorCorresponding Author
Yeon Seok Seo
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Correspondence
Dr Yeon Seok Seo, Department of Internal Medicine, Korea University College of Medicine, 126-1, 5-Ga, Anam-Dong, Seongbuk-Gu, Seoul, 136-705, Korea. Email: [email protected]
Dr Ji Hoon Kim, Department of Internal Medicine, Korea University College of Medicine, 97, Guro-Dong Gil, Guro-Dong, Guro-Ku, Seoul, 152-703, Korea. Email: [email protected]
Search for more papers by this authorCorresponding Author
Ji Hoon Kim
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Correspondence
Dr Yeon Seok Seo, Department of Internal Medicine, Korea University College of Medicine, 126-1, 5-Ga, Anam-Dong, Seongbuk-Gu, Seoul, 136-705, Korea. Email: [email protected]
Dr Ji Hoon Kim, Department of Internal Medicine, Korea University College of Medicine, 97, Guro-Dong Gil, Guro-Dong, Guro-Ku, Seoul, 152-703, Korea. Email: [email protected]
Search for more papers by this authorTae Hyung Kim
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorYang Jae Yoo
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorSeong Hee Kang
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorSun Young Yim
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorSang Jun Suh
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorHyunggin An
Biostatistics, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorHyung Joon Yim
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorJong Eun Yeon
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorKwan Soo Byun
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorSoon Ho Um
Departments of Internal Medicine,, Korea University College of Medicine, Seoul, Korea
Search for more papers by this authorAbstract
Background and Aim:
Although the Barcelona Clinic Liver Cancer (BCLC) staging system is widely used for hepatocellular carcinoma (HCC) staging, the most appropriate BCLC stage designation for single large HCC (SLHCC, single nodule > 5 cm) remains controversial. This study investigated the prognosis of patients with SLHCC.
Methods:
Patients with newly diagnosed HCCs (BCLC stages A or B) were classified according to tumor burden: group 1, a single nodule > 2 and ≤ 5 cm or two or three nodules ≤ 3 cm; group 2, a single nodule > 5 cm; and group 3, two or three nodules > 3 cm or > 3 nodules. Survival analysis was performed according to tumor stage, treatment type, and Child–Pugh grade.
Results:
A total of 1005 patients were enrolled. Age was 59.3 ± 10.6 years, and 788 patients (78.4%) were men. Groups 1, 2, and 3 consisted of 613 (61.0%), 124 (12.3%), and 268 (26.7%) patients, respectively. HCC treatment included resection in 202 patients (20.1%), radiofrequency ablation ± transarterial chemoembolization in 311 patients (30.9%), and transarterial chemoembolization in 492 patients (49.0%). The median survival time differed significantly according to tumor stage (75.2, 44.9, and 30.3 months in groups 1, 2, and 3, respectively; P < 0.001). Multivariate analysis showed that group 2 had significantly worse survival compared with group 1 and similar survival to group 3.
Conclusions:
Patients in group 2 had a worse prognosis than those in group 1 and a similar prognosis to those in group 3. Our results suggest that BCLC stage B is the best stage designation for SLHCC.
Supporting Information
Table S1. Univariate cox-regression analysis for survival.
Figure S1. Flowchart describing the enrolled patients with hepatocellular carcinoma in this study.
| Filename | Description |
|---|---|
| jgh13152-sup-0001-Supplementary.docxWord 2007 document , 17.1 KB | Supporting info item |
| jgh13152-sup-0002-FigS1.tifTIFF image, 224 KB | Flowchart describing the enrolled patients with hepatocellular carcinoma in this study. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Jemal A, Ward E, Hao Y et al. Trends in the leading causes of death in the United States, 1970–2002. JAMA 2005; 294: 1255–9.
- 2Bosch FX, Ribes J, Diaz M et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5–S16.
- 3Lei J, Wang W, Yan L. Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization. J. Gastrointest. Surg. 2013; 17: 1752–9.
- 4Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77: 2217–22.
10.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M CAS PubMed Web of Science® Google Scholar
- 5Minagawa M, Makuuchi M, Takayama T et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann. Surg. 2003; 238: 703–10.
- 6 European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908–43.
- 7Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–2.
- 8Forner A, Reig ME, de Lope CR et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 2010; 30: 61–74.
- 9Cabibbo G, Enea M, Attanasio M et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274–83.
- 10Cillo U, Bassanello M, Vitale A et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J. Hepatol. 2004; 40: 124–31.
- 11Marrero JA, Fontana RJ, Barrat A et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707–16.
- 12Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329–38.
- 13Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907–17.
- 14Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519–24.
- 15Torzilli G, Belghiti J, Kokudo N et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West Study Group. Ann. Surg. 2013; 257: 929–37.
- 16El-Serag HB. Hepatocellular carcinoma. N. Engl. J. Med. 2011; 365: 1118–27.
- 17Grieco A, Pompili M, Caminiti G et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411–8.
- 18Gao Q, Wang XY, Zhou J et al. Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat. Rev. Clin. Oncol. 2015; 12: 10.
- 19Mazzaferro V, Roayaie S, Poon R et al. Dissecting EASL/AASLD recommendations with a more careful knife: a comment on “surgical misinterpretation” of the BCLC staging system. Ann. Surg. 2015; 262: e17–8.
- 20Forner A, Gilabert M, Bruix J et al. Reply: heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat. Rev. Clin. Oncol. 2015; 12: 10.
- 21Bruix J, Fuster J. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? an observational study of the HCC East-West Study Group. Ann. Surg. 2015; 262: e30.
- 22Yin X, Zhang L, Wang YH et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer 2014; 14: 849.
- 23Wang JH, Kee KM, Lin CY et al. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2015; 30: 358–63.
- 24Pawlik TM, Delman KA, Vauthey JN et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005; 11: 1086–92.
- 25Eguchi S, Takatsuki M, Hidaka M et al. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J. Surg. 2010; 34: 1034–8.
- 26Tsai TJ, Chau GY, Lui WY et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000; 127: 603–8.
- 27Llovet JM, Bruix J, Fuster J et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998; 27: 1572–7.
- 28Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334: 693–9.
- 29Yao FY, Xiao L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am. J. Transplant. 2007; 7: 2587–96.
- 30Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10: 35–43.
- 31Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 646–9.
- 32Fan ST, Lai EC, Lo CM et al. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch. Surg. 1995; 130: 198–203.
- 33Guo Z, Zhong JH, Jiang JH et al. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann. Surg. Oncol. 2014; 21: 3069–76.
- 34Yang LY, Fang F, Ou DP et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann. Surg. 2009; 249: 118–23.
- 35Duvoux C, Roudot-Thoraval F, Decaens T et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986–94 e3; quiz e14-5.
- 36Peng SY, Chen WJ, Lai PL et al. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int. J. Cancer 2004; 112: 44–50.
- 37Benvegnu L, Noventa F, Bernardinello E et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48: 110–5.
- 38Cantarini MC, Trevisani F, Morselli-Labate AM et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am. J. Gastroenterol. 2006; 101: 91–8.
- 39Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J. Am. Coll. Surg. 2002; 194: 592–602.
- 40Ng KK, Vauthey JN, Pawlik TM et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? results from a multi-institutional database. Ann. Surg. Oncol. 2005; 12: 364–73.
- 41Yamashita Y, Taketomi A, Shirabe K et al. Outcomes of hepatic resection for huge hepatocellular carcinoma (≥ 10 cm in diameter). J. Surg. Oncol. 2011; 104: 292–8.
- 42Zhou L, Rui JA, Wang SB et al. Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade. Eur. J. Surg. Oncol. 2011; 37: 521–5.
- 43Choi GH, Han DH, Kim DH et al. Outcome after curative resection for a huge (≥ 10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am. J. Surg. 2009; 198: 693–701.
- 44Taniai N, Yoshida H, Tajiri T. Adaptation of hepatectomy for huge hepatocellular carcinoma. J. Hepatobiliary Pancreat. Surg. 2008; 15: 410–6.
- 45Hsu CY, Hsia CY, Huang YH et al. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann. Surg. Oncol. 2012; 19: 842–9.
- 46Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734–9.
- 47Peng ZW, Zhang YJ, Chen MS et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J. Clin. Oncol. 2013; 31: 426–32.
Citing Literature
